Alloimmunization in Chronic Anemias
Mechanism and Contributing Factors
- Antibodies develop when a patient's immune system recognizes foreign red blood cell antigens on transfused blood as "non-self" and mounts an immune response, producing alloantibodies against these mismatched antigens 1
- In patients with sickle cell disease and thalassemia, alloimmunization rates are exceptionally high due to a combination of large cumulative transfusion burden, chronic inflammatory state, RH genetic diversity, and antigen mismatch between donor and recipient populations 1, 2, 3
Specific Antibody Development Patterns
- The most common alloantibodies formed are directed against Rh antigens (D, C, c, E, e) and K antigen, which historically account for the majority of clinically significant antibodies in these patients 1, 3, 4
Clinical Significance and Consequences
- Once alloimmunization occurs, patients face cascading complications, including difficulty locating compatible blood units for future transfusions, potentially causing life-threatening delays 1, 3
- Patients also face an increased risk of acute and delayed hemolytic transfusion reactions (HTRs), which can be fatal 5, 6
- Hyperhemolysis syndrome can occur, where hemoglobin drops below pre-transfusion levels due to destruction of both transfused and the patient's own red cells 7, 8
Quantitative Risk Data
- Alloimmunization rates vary dramatically based on matching strategy, with ABO/RhD matching only resulting in 3.1 new alloantibodies per 100 transfused units, and Rh (C, E) and K matching resulting in 0.053-0.9 new alloantibodies per 100 units 1, 2, 4
Prevention Strategy
- The American Society of Hematology strongly recommends prophylactic red cell antigen matching for Rh (C, E or C/c, E/e) and K antigens at minimum for all patients with sickle cell disease and thalassemia receiving transfusions, with extended matching providing additional protection 4, 5, 9
- Extended red cell antigen profiling should be obtained at the earliest opportunity—optimally before the first transfusion—using genotyping (preferred) or serology 9